Iron deficiency may be linked to non-dialysis-dependent chronic kidney disease and mortality in patients without anemia, according to results of a nationwide cohort study.While iron is a key component ...

Your kidneys are more important to your health than you may realize. In addition to removing waste from the body, these ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Fresenius Medical Care has seen 18.5% growth, with strong prospects. Learn why FMS stock’s fair value of $34/share makes it a ...

Chronic kidney disease (CKD) is a growing global health concern, significantly contributing to morbidity and mortality rates worldwide. Characterized by a ...

Research highlights the survival benefits of non-drug blood pressure control in dialysis patients with CKD. Ultrafiltration proves more effective than antihypertensives for long-term outcomes.

According to the National Kidney Foundation, 123,000 Americans are on that waitlist. More than a 100,000 of those waiting ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

The approval is based on results from the Phase III FLOW trial demonstrating Ozempic reduced the risk of severe kidney outcomes by 24% compared to placebo, including kidney failure, reduction in ...